Administrative Core

行政核心

• 批准号: 7474413
• 负责人: Joel S. Bennett
• 金额: $ 7.02万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7474413
• 关键词: Administrator; Advisory Committees; Antibodies; Antibody Formation; Apple; Area; Biology; Blood Platelets; Budgets; Businesses; CXCR4 gene; Cardiovascular system; Charge; Complex; Computers; Cytoplasmic Tail; Electronic Mail; Endothelial Cells; Epitopes; Equipment and Supplies; Expenditure; F2R gene; Floor; Flow Cytometry; Funding; Future; Glycoproteins; Hematology; Human; Hybridomas; Individual; Manuscripts; Monitor; Monoclonal Antibodies; Mus; Numbers; PAC1 phosphatase; Participant; Pediatric Hospitals; Pennsylvania; Peptides; Photocopying; Platelet Glycoproteins; Price; Principal Investigator; Production; Recommendation; Research; Research Personnel; Services; Site; Specialist; System; Telephone; Thinking; Thrombin Receptor; Thrombosis; Universities; Visit; Wages; base; chemokine receptor; computerized; cost; day; discount; experience; interest; member; oncology; programs

The Administrative Core is essential for the conduct of this Program Project. It will continue to be based in the administrative area of the Hematology-Oncology Division at the University of Pennsylvania. The Core provides administrative support for the participants in the Program Project, as well as secretarial, and consultative functions and the supplies needed to support these functions. In addition, A. Administrative Functions To provide financial coordination for the Program Project, the Core Unit B leader and an experienced business administrator, Ms. Michele Arlotta, monitor the expenditures of each Project and Core Unit, facilitated by a system of computerized record keeping. Project leaders and Core Unit Leaders will be provided with monthly statements of the financial status of their projects or core units. Core Unit B will also serve to centralize the ordering of supplies and equipment, enabling the business administrator to monitor these expenditures and to take advantage of discounted prices available through the University. The business administrator will also oversee matters relating to the consortia with the Division of Hematology at the Children's Hospital of Pennsylvania and Thomas Jefferson University. B. Secretarial functions The Program Project will make use of 35% of the effort of a secretary, Mrs Terese Manganaro, who is based on the 9th floor of BRB 11/111 of the University of Pennsylvania. Mrs. Manganaro will type manuscripts and correspondence generated by the activities of the Program. She has an Apple Macintosh computer and is electronically networked to each investigator via the University of Pennsylvania E-mail network. C. Common Services and Supplies Core Unit B will provide the photocopying, postage, and telephone service needed to support the activities of the Program Project. D. Consultative functions Core Unit B will provide two types of consultative function. First, at monthly intervals, an outside investigator whose interests coincide with those of the members of the Program Project will be asked to a spend a day at the University, meet with the various Project leaders and Co-Investigators, and present a seminar at the weekly Thrombosis & Cardiovascular Biology Seminar. Funds required for these visitors in excess of those requested in the Core Unit Budget will be provided by other funds available to the Hematology-Oncology Division. Second, an External Advisory Committee composed of three members will be selected if and when the Program Project is re-funded. The Committee will be asked to visit the Program Project on a yearly basis, review its progress, and make specific recommendations regarding future directions. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Continuation Format Page ,329 Principal Investigator/Program Director (Last, First, Middle): Bennett, Joel S. E. Continued Supply of Monoclonal Antibodies Since the inception of this Program Project, a Hybridoma Core (Core A), has produced a number of monoclonal antibodies (mAbs) to platelet and endothelial glycoproteins that have been highly useful to the Program. These include: A. Monoclonal antibodies to platelets glycoproteins allbfJS. Multiple antibodies have been produced by the Core to platelet allbbS and continue to be extensively utilized. These include mAbs specific for allb; (33; the allb(33 complex; activation-specific epitopes on the allb(33 complex; antiidiotypic mAbs to the activation-specific, anti allbps mAb PAC-1; and the cytoplasmic domains of allb and (33. B. Monoclonal antibodies to the human thrombin receptor (PAR1). The Core has had a particularly productive track-record in producing mAbs to epitopes on amino terminus of human PAR1 that have been useful in studies of platelets and endothelial cells. C. Monoclonal antibodies to the human PAR2. Antibodies to the PAR2 amino terminus (SAM11 and SAM12) have also been generated from mice immunized with the peptide, SLIGKVDGTSHVTG, corresponding to the first 14 residues of human PAR-2 starting at the activation site (Arg36-Ser37). The mAbs have been particularly useful for flow cytometry and immunohistochemical studies. D. Miscellaneous antibodies. Additional antibodies produced by the Core that have been used by Core members include mAbs to CD9 and the chemokine receptor CXCR4. At the renewal for Years 16-20, Core A was not recommended. However, because projects in the Program continued to use the mAbs listed above, funds were restored to enable continuing production of the antibodies. In this application, we have not proposed the production of new mAbs within the Program and have not requested continuation of Core A. But all of the project continue to make extensive use of one or more of these mAbs and therefore, we have requested modest partial salary support for a Research Specialist to produce them. Costs for supplies will be charged to individual projects as necessary. Although the Research Specialist does not perform an "administrative" function, she does perform a Program-wide function and we think Core B would be the most appropriate place to request support for her salary.

行政核心对于本计划项目的开展至关重要。它将继续是 总部位于英国大学血液肿瘤学部的行政区域 宾夕法尼亚州。核心为计划项目的参与者提供行政支持， 以及秘书和咨询职能以及支持这些职能所需的用品。 此外， A. 行政职能 为该计划项目提供财务协调，核心单位 B 领导者和经验丰富的 业务管理员 Michele Arlotta 女士，监控每个项目和核心单位的支出， 由计算机化记录保存系统提供便利。项目负责人和核心单位负责人将 提供其项目或核心单位财务状况的月度报表。核心单元B 还将有助于集中订购用品和设备，使业务 管理员监控这些支出并利用可用的折扣价格 通过大学。业务管理员还将监督与联合体相关的事务 与宾夕法尼亚州儿童医院血液科和托马斯·杰斐逊合作 大学。 B. 秘书职能 该计划项目将利用秘书 Terese Manganaro 女士的 35% 的精力，她是 基于宾夕法尼亚大学BRB 11/111 9楼。 Manganaro 女士将打字 该计划活动产生的手稿和信件。她有一个苹果 Macintosh 计算机通过大学电子网络连接到每个研究人员 宾夕法尼亚州电子邮件网络。 C. 共同服务和用品 核心单位 B 将提供支持所需的复印、邮寄和电话服务 计划项目的活动。 D. 咨询职能 核心单元B将提供两种类型的咨询功能。首先，每月进行一次外部 将询问与项目成员兴趣一致的研究者 在大学度过一天，与各个项目负责人和联合研究员会面，以及 在每周的血栓形成与心血管生物学研讨会上发表研讨会。所需资金 超出核心单位预算要求的访客将由其他基金提供 可供血液肿瘤科使用。二、外部顾问委员会组成 如果计划项目得到重新资助，将选出三名成员。委员会将 要求每年对计划项目进行一次走访，回顾其进展情况，并提出具体要求 关于未来方向的建议。 PHS 398/2590（修订版 09/04，重新发布 4/2006） 页面延续格式页面 ,329 首席研究员/项目总监（最后、第一、中间）：Bennett, Joel S. E. 单克隆抗体的持续供应 自该计划项目启动以来，杂交瘤核心（核心 A）已产生了许多 针对血小板和内皮糖蛋白的单克隆抗体 (mAb) 非常有用 到该计划。这些包括： A. 血小板糖蛋白 allbfJS 的单克隆抗体。多种抗体已被 由Core生产的血小板allbbS并继续被广泛利用。其中包括单克隆抗体 专门针对 allb； (33；allb(33 复合物；allb(33 复合物)上的激活特异性表位；抗独特型 针对激活特异性、抗 allbps mAb PAC-1 的 mAb；和 allb 的细胞质结构域 和（33. B. 人凝血酶受体 (PAR1) 的单克隆抗体。核心有一个 在生产针对人 PAR1 氨基末端表位的 mAb 方面具有特别高效的记录 这在血小板和内皮细胞的研究中很有用。 C. 人 PAR2 的单克隆抗体。 PAR2 氨基末端抗体 (SAM11 和 SAM12) 也由用肽 SLIGKVDGTSHVTG 免疫的小鼠产生， 对应于从激活位点 (Arg36-Ser37) 开始的人 PAR-2 的前 14 个残基。 单克隆抗体对于流式细胞术和免疫组织化学研究特别有用。 D. 各种抗体。核心产生的其他抗体已被使用 核心成员包括针对 CD9 和趋化因子受体 CXCR4 的 mAb。 在 16-20 年更新时，不推荐核心 A。然而，由于项目在 计划继续使用上面列出的单克隆抗体，资金已恢复以能够继续 抗体的产生。在本申请中，我们没有提出生产新的单克隆抗体 在该计划内，并且没有要求继续核心 A。但所有项目都继续进行 广泛使用这些单克隆抗体中的一种或多种，​​因此，我们要求适度部分 为研究专家提供工资支持以生产它们。供应品费用将由 必要时的个别项目。尽管研究专家不执行 “管理”职能，她确实执行计划范围内的职能，我们认为核心 B 将是 请求支持她的工资的最合适的地方。